Aptose Biosciences logo
Aptose Biosciences APTO
report update icon

Quarterly report 2026-Q1
added 05-13-2026

Aptose Biosciences Cash Flow 2025-2011 | APTO

Brief overview of Aptose Biosciences's cash movements

The comparison covers five available annual reports between 2021 and 2025.

Cash from operations is below zero at -$22 million, increasing dependence on cash reserves or outside financing.

Positive operating cash flow appeared only 0 times out of five; a stable cash profile has not formed.

Overall picture

Aptose Biosciences has limited cash flow resilience; a return to stable positive cash generation is the main condition for improvement.

Annual Cash Flow Aptose Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-22 M -36 M -44.6 M -32.3 M -43.3 M -33.9 M -21.6 M -23.2 M -10.2 M - - - - - -

Depreciation & Amortization

22 K 32 K 88 K 120 K 150 K 152 K 152 K 87 K 84 K - - - - - -

Accounts Payables

2.91 M 1.26 M 3.49 M 3.34 M 1.7 M 2.17 M 1.96 M 1.32 M 589 K - - - - - -

All numbers in USD currency

Quarterly Cash Flow Aptose Biosciences

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-5.84 M - - -2.8 M - - -5.78 M -11.8 M - -10.5 M -13.5 M -11.3 M - -6.98 M -7.05 M -9.64 M - -8.06 M -8.82 M -10.4 M - -8.27 M -7.16 M -8.11 M - -5.18 M -5.27 M -4.87 M - -4.47 M -9.18 M -4.05 M - -2.07 M -2.63 M -2.64 M - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

2 K - - 3 K - - 8 K 16 K - 20 K 22 K 28 K - 30 K 30 K 32 K - 36 K 35 K 35 K - 37 K 37 K 41 K - 33 K 53 K 29 K - 29 K 19 K 16 K - 20 K 23 K 23 K - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

3.81 M 1.46 M 2.88 M 2.39 M 1.26 M - 7.11 M 2.42 M 3.49 M 2.81 M 3.5 M 5.52 M 6.33 M 2.42 M - 1.14 M 1.7 M 1.63 M 2.91 M 1.61 M 2.17 M 2.17 M 2.17 M 2.17 M 1.96 M 1.96 M 1.96 M 1.96 M 1.32 M 1.32 M 1.32 M 1.32 M 589 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Aptose Biosciences, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
- 7.23 % $ 2.72 M usaUSA
Spectrum Pharmaceuticals Spectrum Pharmaceuticals
SPPI
- - $ 189 M usaUSA
VBI Vaccines VBI Vaccines
VBIV
- -50.87 % $ 1.09 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Decibel Therapeutics Decibel Therapeutics
DBTX
- - $ 123 M usaUSA
IVERIC bio IVERIC bio
ISEE
- - $ 5.51 B usaUSA
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Molecular Templates Molecular Templates
MTEM
- -23.43 % $ 495 K usaUSA
CohBar CohBar
CWBR
- -15.44 % $ 2.2 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
- - $ 105 M usaUSA
Global Blood Therapeutics Global Blood Therapeutics
GBT
- - $ 4.62 B usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Infinity Pharmaceuticals Infinity Pharmaceuticals
INFI
- -46.98 % $ 3.57 M usaUSA
Novan Novan
NOVN
- -24.84 % $ 2.64 M usaUSA
NanoString Technologies NanoString Technologies
NSTG
- -37.43 % $ 5.1 M usaUSA
Orgenesis Orgenesis
ORGS
- -33.86 % $ 61.2 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Inozyme Pharma Inozyme Pharma
INZY
- - $ 207 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
- -29.58 % $ 126 M usaUSA
Surface Oncology Surface Oncology
SURF
- - $ 59.7 M usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 13.35 0.45 % $ 863 M usaUSA
Inhibrx Inhibrx
INBX
$ 100.08 0.03 % $ 4.72 B usaUSA
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 0.48 2.6 % $ 5.91 B israelIsrael
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 1.11 16.39 % $ 118 M britainBritain
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
$ 2.3 4.08 % $ 1.55 B israelIsrael
Zymeworks Zymeworks
ZYME
$ 26.49 0.81 % $ 1.37 B canadaCanada
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 0.07 9.81 % $ 855 K usaUSA
Theravance Biopharma Theravance Biopharma
TBPH
$ 17.03 0.03 % $ 857 M cayman-islandsCayman-islands
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA